help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stockley, R. A.
Right arrow Articles by Dowson, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stockley, R. A.
Right arrow Articles by Dowson, L. J.
American Journal of Respiratory and Critical Care Medicine Vol 165. pp. 1494-1498, (2002)
© 2002 American Thoracic Society

Original Article

The Effect of Augmentation Therapy on Bronchial Inflammation in {alpha}1-Antitrypsin Deficiency

Robert A. Stockley, Darren L. Bayley, Ipek Unsal and Lee J. Dowson

Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom

Correspondence and requests for reprints should be addressed to Professor Robert A. Stockley, Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. E-mail: r.a.stockley{at}bham.ac.uk

{alpha}1-Antitrypsin (AAT) deficiency predisposes to bronchitis and emphysema associated with neutrophilic airway inflammation. The efficacy of augmentation therapy has not been proven clinically or by demonstrating an effect on airway inflammation. We treated 12 patients with four infusions of Prolastin (60 mg/kg) at weekly intervals and monitored both the serum and secretion concentrations of AAT as well as markers of neutrophilic inflammation, including myeloperoxidase, elastase, and the neutrophil chemoattractants interleukin-8 and leukotriene B4. Serum AAT rose and was maintained above the protective threshold. In addition, AAT concentrations in the sputum rose from a mean of 0.17 µM (SEM ± 0.04) before therapy to concentrations similar to nondeficient subjects (0.43 ± 0.12) 1 week after the first infusion (p < 0.01). This was associated with a reduction in elastase activity (p < 0.002) and the chemoattractant leukotriene B4 (p < 0.02), which fell from a median baseline value of 13.46 nM (range, 4.17–55.00) to 8.62 nM (4.23–21.59) the day following the last infusion. Although median values for myeloperoxidase and interleukin-8 also fell, the changes failed to achieve statistical significance. In summary, short-term therapy with AAT increased lung secretion concentrations and was associated with a fall in leukotriene B4, which is thought to be central to the airway inflammation of AAT deficiency.

Key Words: {alpha}1-antitrypsin • sputum • inflammation • leukotriene B4




This article has been cited by other articles:


Home page
 Eur Respir JHome page
B. Gooptu, U. I. Ekeowa, and D. A. Lomas
Mechanisms of emphysema in {alpha}1-antitrypsin deficiency: molecular and cellular insights
Eur. Respir. J., August 1, 2009; 34(2): 475 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Luisetti, S. Ma, P. Iadarola, P. J. Stone, S. Viglio, B. Casado, Y. Y. Lin, G. L. Snider, and G. M. Turino
Desmosine as a biomarker of elastin degradation in COPD: current status and future directions
Eur. Respir. J., November 1, 2008; 32(5): 1146 - 1157.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
P Geraghty, M P Rogan, C M Greene, M L Brantly, S J O'Neill, C C Taggart, and N G McElvaney
Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro
Thorax, July 1, 2008; 63(7): 621 - 626.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
G. Tirado-Conde, B. Lara, and M. Miravitlles
Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency
Therapeutic Advances in Respiratory Disease, February 1, 2008; 2(1): 13 - 21.
[Abstract] [PDF]

Home page
 Proc Am Thorac SocHome page
E. F. M. Wouters, K. H. Groenewegen, M. A. Dentener, and J. H. J. Vernooy
Systemic Inflammation in Chronic Obstructive Pulmonary Disease: The Role of Exacerbations
Proceedings of the ATS, December 1, 2007; 4(8): 626 - 634.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Churg, X. Wang, R. D. Wang, S. C. Meixner, E. L. G. Pryzdial, and J. L. Wright
{alpha}1-Antitrypsin Suppresses TNF-{alpha} and MMP-12 Production by Cigarette Smoke-Stimulated Macrophages
Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 144 - 151.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D Soy, C de la Roza, B Lara, C Esquinas, A Torres, and M Miravitlles
Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics
Thorax, December 1, 2006; 61(12): 1059 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. I. Rennard
Antiinflammatory Therapies Other Than Corticosteroids
Proceedings of the ATS, November 1, 2004; 1(3): 282 - 287.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R A Sandhaus
{alpha}1-Antitrypsin deficiency {middle dot} 6: New and emerging treatments for {alpha}1-antitrypsin deficiency
Thorax, October 1, 2004; 59(10): 904 - 909.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J K Stoller and L S Aboussouan
{alpha}1-Antitrypsin deficiency {middle dot} 5: Intravenous augmentation therapy: current understanding
Thorax, August 1, 2004; 59(8): 708 - 712.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. T. Mulgrew, C. C. Taggart, M. W. Lawless, C. M. Greene, M. L. Brantly, S. J. O'Neill, and N. G. McElvaney
Z {alpha}1-Antitrypsin Polymerizes in the Lung and Acts as a Neutrophil Chemoattractant
Chest, May 1, 2004; 125(5): 1952 - 1957.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Needham and R A Stockley
{alpha}1-Antitrypsin deficiency * 3: Clinical manifestations and natural history
Thorax, May 1, 2004; 59(5): 441 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Luisetti
You May Say That I Ain't Free--But It Don't Worry Me
Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 144 - 145.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Churg, R. D. Wang, C. Xie, and J. L. Wright
{alpha}-1-Antitrypsin Ameliorates Cigarette Smoke-induced Emphysema in the Mouse
Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 199 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 356 - 370.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. Brantly
{alpha}1-Antitrypsin: Not Just an Antiprotease: Extending the Half-Life of a Natural Anti-Inflammatory Molecule by Conjugation with Polyethylene Glycol
Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 652 - 654.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  Work-Life